NMN and the Science of Cellular Energy

What NAD biology explains — and what human trials have yet to establish.

When an ingredient is described as supporting cellular energy, it is easy to imagine a noticeable change: a clearer morning, an easier workout, fewer afternoons spent running on empty. NMN has attracted attention partly because its biology seems to offer a route to those experiences. The connection is more complicated than the phrase suggests.

NMN participates in the production of NAD⁺, a molecule essential to cellular metabolism. Human trials show that supplementation can change NAD-related measurements. Whether those changes consistently improve daily energy, physical performance or long-term health is a different question. Understanding that distinction is the best place to begin. [1, 7]

What NMN Actually Is

NMN stands for nicotinamide mononucleotide. It is a nucleotide involved in the body's pathways for making nicotinamide adenine dinucleotide, usually written as NAD⁺. Enzymes called NMN adenylyltransferases convert NMN into NAD⁺. The body also makes and recycles NAD⁺ through other routes, so this is a regulated metabolic network rather than a single reservoir waiting to be topped up. [1]

NAD⁺ and its reduced form, NADH, help transfer electrons during reactions that extract energy from nutrients. Those reactions connect to mitochondrial ATP production. ATP supplies usable energy for cellular work. NAD⁺ also serves as a substrate for enzymes involved in processes such as DNA repair and cellular signaling. None of this means that an NMN capsule directly supplies ATP, repairs a person's DNA or produces an immediate feeling of energy. [1]

NR, or nicotinamide riboside, is another NAD⁺ precursor. NMN and NR are related, but they are not interchangeable ingredients. A trial of NR cannot establish the effects of NMN, and a trial of one NMN preparation does not automatically establish the effects of every commercial formulation. [1, 7]

Why Aging Researchers Study It

Research has documented changes in NAD⁺ metabolism with aging in experimental models and in some human tissues. These changes have prompted scientists to test whether altering precursor availability can influence cellular function. However, tissue, health status and measurement method matter; age alone does not establish that someone has a clinically meaningful NAD⁺ deficiency. [1]

The distinction between compartments is also important. A blood measurement is not a direct reading of NAD⁺ inside every muscle cell or within its mitochondria. Higher circulating or blood-cell NAD-related values show a biological response, but they do not by themselves demonstrate better stamina, younger cells or a longer life. [1, 7]

What the Human Trials Found

A Small Metabolic Trial

In a randomized, double-blind trial published in Science in 2021, researchers studied postmenopausal women with prediabetes who were overweight or obese over ten weeks. NMN supplementation was associated with changes in insulin-stimulated glucose disposal and skeletal muscle insulin signaling. The study used specialized metabolic testing rather than relying only on routine fasting blood measurements. [2]

This is a meaningful research observation in a defined population. It is not evidence that NMN treats diabetes, prevents progression from prediabetes, causes weight loss or produces the same response in healthy men and women. The study was short and was not designed to answer those clinical questions. [2]

Exercise Results Need Their Training Context

A 2021 trial enrolled 48 recreational runners for six weeks. Participants received placebo or 300, 600 or 1,200 mg of NMN per day while following an exercise-training program. The medium- and higher-dose groups improved more on some ventilatory-threshold measures, which describe how the body responds as exercise intensity rises. However, the study did not show corresponding between-group advantages in maximal oxygen uptake or peak power. [3]

All groups trained. The result therefore concerns NMN in that training setting, not a capsule replacing exercise. With only 12 participants per group and predominantly male runners, the findings are also too narrow to predict the response of a sedentary older adult. The doses describe the experiment; they are not personal dosing recommendations. [3]

A Walking and Sleep Study With a Null Primary Outcome

A 2024 randomized trial assigned 60 older adults to 250 mg of NMN daily or placebo for 12 weeks. Its primary stepping-test outcome did not differ significantly between groups. Some secondary measures favored NMN, including four-meter walking time, NAD-related blood measurements and selected sleep-questionnaire scores. [4]

That combination deserves a careful reading. The positive secondary findings suggest questions for further study, but they do not erase the null primary outcome. Questionnaire scores also cannot establish that NMN treats insomnia. When a trial examines many outcomes, replication and the prespecified analysis become especially important. [4]

What the Broader Evidence Adds

A 2025 systematic review and meta-analysis evaluated NMN and NR studies involving adults whose mean ages were above 60. For NMN, pooled results did not show significant improvements in skeletal muscle index, handgrip strength, gait speed or the five-chair-stand test. The review does not prove that every possible NMN intervention is ineffective, but it argues against presenting muscle preservation as an established benefit. [5]

A July 2026 review included 15 trials of oral NMN or NMN-related preparations, with ten contributing to safety analyses. Study durations ranged from 14 days to 24 weeks. It found no significant pooled effects on body weight, BMI, fasting glucose, HbA1c or lipid profiles. A small diastolic blood-pressure signal was exploratory and did not establish NMN as a blood-pressure treatment. The included populations and preparations varied. [6]

A separate 2026 review of 113 human and rodent studies reached a compatible conclusion: biochemical responses to NAD-related interventions were more consistent than functional or broader health outcomes in people. Its total included 33 human intervention studies, not 113 human trials. [7]

How to Think About Safety and Product Claims

The 2026 safety analysis found no clear short-term increase in reported adverse events or measured liver-enzyme abnormalities. That is useful information within the studied conditions, not proof of safety over years. Small studies cannot reliably rule out uncommon adverse effects, and their results do not establish safety during pregnancy or breastfeeding or with every medication. [6]

An ingredient's purity, dose, formulation and storage conditions are separate questions from its proposed biology. A certificate of analysis can help document what is in a product; it cannot establish that the product improves health. Likewise, a higher dose on a label does not establish a larger benefit.

For someone reading the science, three questions are more useful than a promise of cellular rejuvenation: What was measured? In whom? Compared with what? NMN remains an active area of research. The most defensible interpretation is that it can alter NAD biology under studied conditions, while reliable improvements in everyday function and long-term outcomes remain unsettled. [5–7]

References

1. Covarrubias AJ et al. NAD⁺ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2). doi.org/10.1038/s41580-020-00313-x
2. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547). doi.org/10.1126/science.abe9985
3. Liao B et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. Journal of the International Society of Sports Nutrition. 2021;18(1). doi.org/10.1186/s12970-021-00442-4
4. Morifuji M et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. GeroScience. 2024;46(5). PubMed
5. Prokopidis K et al. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(3). PMC
6. Yang W et al. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults. Nutrients. 2026;18(14).
7. Gallagher C et al. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review. Ageing Research Reviews. 2026;116.